A series of cardiometabolic-related news items has been observed from Amgen, Dexcom, Zealand Pharma, Esperion Therapeutics, Senseonics, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.
Recently, Zealand announced topline 42-week results from the Ph2 ZUPREME-1 study, which evaluated petrelintide (QW SC amylin analog) in adults with obesity or overweight (previous FENIX insight). Following the announcement, Zealand’s share price declined -36%, reflecting investor disappointment in petrelintide’s weight loss efficacy (up to -10.7%), despite an otherwise favorable tolerability profile. Below, FENIX provides a thoughts-on analysis of the topline ZUPREME-1 data, including a deep-dive on how petrelintide’s benefit/risk profile compares to other amylin analogs in development, as well as why amylin may fall short of Zealand’s expectations for it becoming the next foundational AOM.
Novo Nordisk hosted its Q4 ’25 earnings call (view press release; view slides) and provided updates across its diabetes and obesity business. Of note, the company’s stock is down ~20% following lower than expected FY 2026 sales guidance of -5% to -13%, vs. the Street’s low-single-digit expectations (view article). Management attributed the outlook to increased incretin pricing pressure, intensifying US competition, and ex-US patent expiries. Of note, Novo will be hosting its 2026 Capital Markets Day on September 21 in London, UK. Below, FENIX provides highlights and insights from the Q4 ’25 earnings call.
Three cardiometabolic-related items have been observed: Zealand hosted its Q2 ‘25 earnings call (press release; slides); Lilly is reportedly increasing Mounjaro pricing in the UK to match EU pricing (view article); and Superluminal announced it entered into a drug discovery agreement with Lilly (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Lilly, Ascletis Pharma, and Zealand Pharma. Below, FENIX provides highlights and insights for the respective news items.
Zealand Pharma and Roche announced a licensing and collaboration deal to co-develop and co-commercialize petrelintide (amylin analog) monotherapy and in combination with CT-388 (GLP-1/GIP dual agonist; discussed below) in obesity. Of note, Zealand hosted an associated webcast (view slides). Zealand’s stock increased ~40% following the announcement. Below, FENIX provides highlights and insights for the partnership agreement, including thoughts on how Roche may have needed the petrelintide deal to save its Carmot acquisition.
In the first installment of FENIX’s Obesity Spotlight Series, FENIX has conducted a deep dive analysis of Zealand Pharma’s place in the obesity market, including a sit-down interview with Zealand’s CEO Adam Steensberg. The analysis includes insights and thoughts on Zealand’s partnership/M&A strategy as it looks to advance its obesity pipeline, particularly petrelintide.
Zealand FY Q4 ‘24 Earnings; Steve Pacelli Leaves Dexcom
On the first day of JPM 2025, FENIX has provided coverage of presentations by major CVRM companies, including Dexcom, Amgen, Viking, Pfizer, Zealand, Medtronic, Regeneron, Vertex, Alnylam, and Cytokinetics. Roche also presented at JPM 2025 but had no meaningful discussion relating to its CVRM portfolio. Additionally, a series of CVRM-related news items have been observed:
During the holiday break, a series of cardiometabolic-related news items were observed from Lilly, NICE, Dexcom/Abbott, Arrowhead Pharmaceuticals, AstraZeneca, Zealand Pharma, Biocon/Hakima, and Lexicon Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.